Michael Nofi
CIK: 0001705477
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (10 total)
- Aug 12, 2026EWTX
Edgewise Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
48.8K shares- - Aug 12, 2026EWTX
Edgewise Therapeutics, Inc.
Award(A)DirectRestricted Stock Units
24.4K shares- - Aug 12, 2026EWTX
Edgewise Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
48.8K shares- - Nov 10, 2025EWTX
Edgewise Therapeutics, Inc.
Award(A)DirectStock Options (Right to buy)
262.5K shares- - Nov 10, 2025EWTX
Edgewise Therapeutics, Inc.
Award(A)DirectRestricted Stock Units
43.8K shares- - Jul 1, 2025SWTX
SpringWorks Therapeutics, Inc.
Disposition(D)Direct30.6K shares- - Jan 10, 2025SWTX
SpringWorks Therapeutics, Inc.
Award(A)Direct6.9K shares- - Jan 6, 2025SWTX
SpringWorks Therapeutics, Inc.
Tax Payment(F)Direct1K shares at avg. $38.86$39K - Jan 5, 2025SWTX
SpringWorks Therapeutics, Inc.
Tax Payment(F)Direct1.6K shares at avg. $38.19$62K - Jan 4, 2025SWTX
SpringWorks Therapeutics, Inc.
Tax Payment(F)Direct2.4K shares at avg. $38.19$91K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 12, 2026 |  EWTX Edgewise Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 48,750 | - | - | Direct |
| Aug 12, 2026 | EWTX Edgewise Therapeutics, Inc. | Award(A) Restricted Stock Units | 24,375 | - | - | Direct |
| Aug 12, 2026 | EWTX Edgewise Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 48,750 | - | - | Direct |
| Nov 10, 2025 | EWTX Edgewise Therapeutics, Inc. | Award(A) Stock Options (Right to buy) | 262,500 | - | - | Direct |
| Nov 10, 2025 | EWTX Edgewise Therapeutics, Inc. | Award(A) Restricted Stock Units | 43,750 | - | - | Direct |
| Jul 1, 2025 |  SWTX SpringWorks Therapeutics, Inc. | Disposition(D) | 30,623 | - | - | Direct |
| Jan 10, 2025 | SWTX SpringWorks Therapeutics, Inc. | Award(A) | 6,929 | - | $0 | Direct |
| Jan 6, 2025 | SWTX SpringWorks Therapeutics, Inc. | Tax Payment(F) | 1,009 | $38.86 | $39,210 | Direct |
| Jan 5, 2025 | SWTX SpringWorks Therapeutics, Inc. | Tax Payment(F) | 1,636 | $38.19 | $62,479 | Direct |
| Jan 4, 2025 | SWTX SpringWorks Therapeutics, Inc. | Tax Payment(F) | 2,388 | $38.19 | $91,198 | Direct |
1-10 of 10 transactions
About Nofi Michael
Nofi Michael (SEC CIK 0001705477) files insider reports with the SEC as Chief Financial Officer of Edgewise Therapeutics, Inc. (EWTX) and Chief Accounting Officer of SpringWorks Therapeutics, Inc. (SWTX).
Signal8 holds 7 ownership filings by Nofi Michael (1 Form 3, 6 Form 4), filed between Jan 7, 2025 and Aug 17, 2026. Those filings report 10 transactions, from Jan 4, 2025 to Aug 12, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Nofi Michael's filings is in BOULDER, CO.
Recent filings by Nofi Michael
- Aug 12, 2026: Grants or awards of EWTX derivative securities (3 lines, Form 4, code A).
- Nov 10, 2025: Grants or awards of EWTX derivative securities (2 lines, Form 4, code A).
- Jul 1, 2025: Disposition to issuer transaction of SWTX shares (Form 4, code D).
- Jan 10, 2025: Grant or award of SWTX shares (Form 4, code A).
- Jan 6, 2025: Tax withholding of SWTX shares (Form 4, code F).
Other insiders filing for Edgewise Therapeutics, Inc. (EWTX)
- Fox Jonathan C, Director
- Donovan Joanne M., CMO
- Russell Alan J, Chief Scientific Officer
- MOORE JOHN R, General Counsel
- Derakhshan Behrad, Chief Business Officer
- KOCH KEVIN, President and CEO